Cholestatic Jaundice Induced by Duloxetine in a Patient with Major Depressive Disorder
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Young-Min | - |
dc.contributor.author | Lee, Bun-Hee | - |
dc.contributor.author | Lee, Heon-Jeong | - |
dc.contributor.author | Kang, Seung-Gul | - |
dc.date.accessioned | 2021-09-08T00:24:43Z | - |
dc.date.available | 2021-09-08T00:24:43Z | - |
dc.date.created | 2021-06-14 | - |
dc.date.issued | 2010-09 | - |
dc.identifier.issn | 1738-3684 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/115736 | - |
dc.description.abstract | Duloxetine is a balanced and potent serotonin and noradrenaline reuptake inhibitor (SNRI) and has adverse effects that are commonly associated with such drugs, including nausea, dry mouth, constipation, insomnia, and dizziness. Recently, duloxetine-induced liver injury has also been observed in patients with preexisting liver disease or chronic alcohol use. We investigated the effects of duloxetine in a healthy young adult with major depressive disorder (MDD) but no risk factors, and found that his total bilirubin level increased to 3.3 mg/dL and he developed jaundice after 5 months of duloxetine treatment. Discontinuation of duloxetine treatment saw his total bilirubin level decrease to 1.8 mg/dL. Thus, the administration of duloxetine might induce liver injury in a patient with MDD. However, the limitations of this single case report must be acknowledged. Although the cause of hepatic dysfunction in this case remains to be elucidated, clinicians should monitor liver function carefully after duloxetine treatment. Further investigations with a larger sample are needed. Psychiatry Investig 2010;7:228-230 | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN NEUROPSYCHIATRIC ASSOC | - |
dc.subject | HEPATIC SAFETY PROFILE | - |
dc.subject | INDUCED LIVER-INJURY | - |
dc.subject | FAILURE | - |
dc.title | Cholestatic Jaundice Induced by Duloxetine in a Patient with Major Depressive Disorder | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Heon-Jeong | - |
dc.identifier.doi | 10.4306/pi.2010.7.3.228 | - |
dc.identifier.scopusid | 2-s2.0-77957727317 | - |
dc.identifier.wosid | 000282016300012 | - |
dc.identifier.bibliographicCitation | PSYCHIATRY INVESTIGATION, v.7, no.3, pp.228 - 230 | - |
dc.relation.isPartOf | PSYCHIATRY INVESTIGATION | - |
dc.citation.title | PSYCHIATRY INVESTIGATION | - |
dc.citation.volume | 7 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 228 | - |
dc.citation.endPage | 230 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001548491 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Psychiatry | - |
dc.relation.journalWebOfScienceCategory | Psychiatry | - |
dc.subject.keywordPlus | HEPATIC SAFETY PROFILE | - |
dc.subject.keywordPlus | INDUCED LIVER-INJURY | - |
dc.subject.keywordPlus | FAILURE | - |
dc.subject.keywordAuthor | Duloxetine | - |
dc.subject.keywordAuthor | Liver injury | - |
dc.subject.keywordAuthor | Hepatic dysfunction | - |
dc.subject.keywordAuthor | Hepatotoxicity | - |
dc.subject.keywordAuthor | Major depressive disorder | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.